(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
0.00% $ 182.50
Live Chart Being Loaded With Signals
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD)...
Stats | |
---|---|
Volumen de hoy | 3.00 |
Volumen promedio | 4.22M |
Capitalización de mercado | 0.00 |
EPS | $0 ( 2021-07-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 59.23 |
ATR14 | $1.935 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-07-21 | Coughlin Christopher J | Sell | 42 347 | Common Stock, par value $.0001 per share |
2021-07-21 | Coughlin Christopher J | Sell | 2 294 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 706 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 343 | Option to Purchase Common Stock |
2021-07-21 | Sarin Aradhana | Sell | 120 253 | Common Stock, par value $.0001 per share |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 1 094 307 | Sell: 1 860 897 |
Volumen Correlación
Alexion Pharmaceuticals, Correlación
10 Correlaciones Más Positivas | |
---|---|
CREC | 0.977 |
FLXS | 0.977 |
PRSR | 0.976 |
LDHA | 0.976 |
PWUP | 0.973 |
MSDAU | 0.973 |
CRZN | 0.972 |
VLAT | 0.97 |
FXCO | 0.968 |
TIOAU | 0.967 |
10 Correlaciones Más Negativas | |
---|---|
MESA | -0.979 |
MBIO | -0.979 |
JG | -0.977 |
MLKN | -0.975 |
FWRD | -0.975 |
RENT | -0.974 |
GERN | -0.974 |
NXTC | -0.974 |
WKEY | -0.972 |
ATHA | -0.971 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Alexion Pharmaceuticals, Correlación - Moneda/Commodity
Alexion Pharmaceuticals, Finanzas
Annual | 2020 |
Ingresos: | $6.07B |
Beneficio Bruto: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2020 |
Ingresos: | $6.07B |
Beneficio Bruto: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2019 |
Ingresos: | $4.99B |
Beneficio Bruto: | $4.60B (92.10 %) |
EPS: | $10.77 |
FY | 2018 |
Ingresos: | $4.13B |
Beneficio Bruto: | $3.76B (90.94 %) |
EPS: | $0.348 |
Financial Reports:
No articles found.
Alexion Pharmaceuticals,
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico